SYBX
Synlogic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.22
+0.00%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$15.03M
MomentumView details →
1D Return
+0.00%
YTD Return
+8.93%
RSI (14)
67.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$15.03M
RSI (14)
67.1
MomentumView details →
1D Return
+0.00%
YTD Return
+8.93%
SummaryUpdated Jun 1, 2026
Synlogic, Inc. (NASDAQ:SYBX) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts. The company went public in September 2015 and focuses on developing synthetic biotic medicines, which are engineered microorganisms designed to treat metabolic and immunological diseases. Synlogic represents a novel approach in biotechnology, using genetically modified bacteria as therapeutic agents rather than traditional small molecule drugs or biologics.
Similar companies
Latest newsMore news →